{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:18:03Z","timestamp":1790093883716,"version":"4.0.1"},"reference-count":15,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":4430,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[1999,12]]},"abstract":"<jats:p>Pergolide is a dopaminergic agonist used to treat Parkinson's disease but is associated with the development of retroperitoneal fibrosis (RPF). Newer nonergot agents (pramipexole, ropinirole) may not carry this same risk. A patient with a history of pergolide\u2010induced RPF was treated successfully with ropinirole for 1 year without complications.<\/jats:p>","DOI":"10.1592\/phco.19.18.1437.30888","type":"journal-article","created":{"date-parts":[[2004,4,27]],"date-time":"2004-04-27T05:52:53Z","timestamp":1083045173000},"page":"1437-1438","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Treatment of Parkinson's Disease with Ropinirole after Pergolide\u2010Induced Retroperitoneal Fibrosis"],"prefix":"10.1002","volume":"19","author":[{"given":"Brian C.","family":"Lund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"Neiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.1_Suppl_1.S34"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199506000-00009"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.1998.00603.x"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198604000-00012"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)92178-1"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.298.6683.1315-a"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1989.tb06026.x"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1991.tb03011.x-i1"},{"key":"e_1_2_1_10_2","first-page":"179","article-title":"Ergotamine as a possible cause of retroperitoneal fibrosis","volume":"1","author":"Lepage\u2010Savary D.","year":"1982","journal-title":"Clin Pharm"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196602172740701"},{"key":"e_1_2_1_12_2","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0022-5347(17)63538-9","article-title":"Reversible retroperitoneal fibrosis with ureteral obstruction associated with ingestion of Sansert","volume":"95","author":"Weiss JM","year":"1966","journal-title":"J Urol"},{"key":"e_1_2_1_13_2","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1001\/jama.1968.03150050029005","article-title":"Silent retroperitoneal fibrosis associated with methysergide therapy","volume":"206","author":"Elkind AH","year":"1968","journal-title":"JAMA"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.104.3.566"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)59635-4"},{"key":"e_1_2_1_16_2","first-page":"77","article-title":"Retroperitoneal fibrosis in two patients previously exposed to LSD","volume":"113","author":"Aptekar RG","year":"1970","journal-title":"California Med"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.19.18.1437.30888","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.19.18.1437.30888","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:45:19Z","timestamp":1761050719000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.19.18.1437.30888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,12]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[1999,12]]}},"alternative-id":["10.1592\/phco.19.18.1437.30888"],"URL":"https:\/\/doi.org\/10.1592\/phco.19.18.1437.30888","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,12]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}